# Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS

Source: https://onco.cc/trials/nct06533761/  
OnCo record `nct06533761` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Eganelisib run by Stelexis BioSciences, now recruiting.

## Summary

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS is a phase 1 interventional study registered as NCT06533761 by Stelexis BioSciences, with 105 participants planned, started 2025-04-28. Conditions recorded: AML, Adult and MDS. Interventions recorded: Eganelisib, Eganelisib in combination with cytarabine, Eganelisib in combination with azacitidine and Azacitadine (AZA).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06533761
- Phase: 1
- Setting: A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Higher Risk Myelodysplastic Syndrome and Eganelisib in Combination With Azacitidine in PI3K-Gamma-Positive Patients With Previously Untreated Higher Risk Myelodysplastic Syndrome
- Sponsor: Stelexis BioSciences
- Enrolled: 105

## Sources

- ClinicalTrials.gov NCT06533761: https://clinicaltrials.gov/study/NCT06533761

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [Eganelisib](https://onco.cc/drugs/eganelisib/)
- companies: [Stelexis BioSciences](https://onco.cc/companies/stelexis-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06533761.json